Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Janux Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
JANX
Nasdaq
2834
www.januxrx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Janux Therapeutics, Inc.
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
- Jan 24th, 2025 9:01 pm
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
- Dec 7th, 2024 12:43 am
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- Dec 5th, 2024 4:12 am
Why Janux Therapeutics Crushed the Market Today
- Dec 4th, 2024 11:23 pm
JANX Stock Hits Record High on Prostate Cancer Study Data
- Dec 4th, 2024 3:04 pm
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride
- Dec 3rd, 2024 9:07 pm
Janux Therapeutics Announces Proposed Public Offering
- Dec 3rd, 2024 9:01 pm
Sector Update: Health Care Stocks Mixed Late Afternoon
- Dec 3rd, 2024 8:41 pm
Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz
- Dec 3rd, 2024 4:58 pm
Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results
- Dec 3rd, 2024 4:20 pm
Janux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a Year
- Dec 3rd, 2024 3:01 pm
Janux impresses Wall Street with new prostate cancer drug results
- Dec 3rd, 2024 11:13 am
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
- Dec 2nd, 2024 9:30 pm
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
- Nov 25th, 2024 2:00 pm
Janux Therapeutics initiated with an Outperform at Leerink
- Nov 23rd, 2024 11:21 am
Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors
- Nov 16th, 2024 1:34 am
Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations
- Nov 8th, 2024 10:07 am
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
- Nov 6th, 2024 9:01 pm
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
- Oct 16th, 2024 1:20 pm
Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now
- Oct 7th, 2024 9:08 pm
Scroll